* history of any illness or history or presence of clinically significant pathology that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject or collecting samples for analysis. this includes, but is not limited to, a history of relevant drug or food allergies; history of clinically significant cardiovascular, pulmonary, autoimmune, psychiatric or central nervous system disease, or of cancer with systemic spread in remission for less than 5 years. * use of any medications started within 14 days (or 5 half-lives, whichever is longer) prior to study drug administration including, prescription medications, nutritional supplements, and over-the-counter medications except for vitamin supplements, hormonal contraception, and recommended doses of acetaminophen, aspirin or ibuprofen * hospitalization for any reason within 60 days prior to the screening visit * history of or positive human immunodeficiency virus (hiv) screen result, or positive blood test for hepatitis b surface antigen (hbsag) or hepatitis b core antibody (hbcab). subjects with positive hepatitis c virus (hcv) antibody at the screening visit are only eligible if they have previously completed treatment for hcv and have confirmatory negative test for hcv rna. * history of drug or alcohol abuse within 1 year prior to screening, or positive test for drugs of potential abuse at screening and admission, where alcohol abuse is defined as regular consumption exceeding 7 drinks/ week for women, and 14 drinks/ week for men. * participation (defined as receipt of dose of investigational agent) in any clinical research study evaluating another investigational drug or therapy within 30 days or at least 5 half-lives (whichever is longer), of the investigational drug prior to the screening visit * blood donation of approximately 1 pint (500 ml) within 60 days prior to dosing, or donation of more than 1 unit of plasma within 30 days prior to the start of study drug dosing * receipt of any transfused blood products within 60 days of the screening visit. * any history of receiving treatment or vaccination against sars-cov-2 * febrile illness within 28 days prior to the first dose of study drug, or other signs or symptoms consistent with sars-cov-2 infection in the judgement of the investigator in the 14 days prior to the first dose of study drug.

* history of any illness or history or presence of clinically significant pathology that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject or collecting samples for analysis. this includes, but is not limited to, a history of relevant drug or food allergies; history of clinically significant cardiovascular, pulmonary, autoimmune, psychiatric or central nervous system disease, or of cancer with systemic spread in remission for less than 5 years. * use of any medications started within 14 days (or 5 half-lives, whichever is longer) prior to study drug administration including, prescription medications, nutritional supplements, and over-the-counter medications except for vitamin supplements, hormonal contraception, and recommended doses of acetaminophen, aspirin or ibuprofen * hospitalization for any reason within 60 days prior to the screening visit * history of or positive human immunodeficiency virus (hiv) screen result, or positive blood test for hepatitis b surface antigen (hbsag) or hepatitis b core antibody (hbcab). subjects with positive hepatitis c virus (hcv) antibody at the screening visit are only eligible if they have previously completed treatment for hcv and have confirmatory negative test for hcv rna. * history of drug or alcohol abuse within 1 year prior to screening, or positive test for drugs of potential abuse at screening and admission, where alcohol abuse is defined as regular consumption exceeding 7 drinks/ week for women, and 14 drinks/ week for men. * participation (defined as receipt of dose of investigational agent) in any clinical research study evaluating another investigational drug or therapy within 30 days or at least 5 half-lives (whichever is longer), of the investigational drug prior to the screening visit * blood donation of approximately 1 pint (500 ml) within 60 days prior to dosing, or donation of more than 1 unit of plasma within 30 days prior to the start of study drug dosing * receipt of any transfused blood products within 60 days of the screening visit. * any history of receiving treatment or vaccination against sars-cov-2 * febrile illness within 28 days prior to the first dose of study drug, or other signs or symptoms consistent with sars-cov-2 infection in the judgement of the investigator in the 14 days prior to the first dose of study drug.

- history of any illness or history or presence of clinically significant pathology that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject or collecting samples for analysis. this includes, but is not limited to, a history of relevant drug or food allergies; history of clinically significant cardiovascular, pulmonary, autoimmune, psychiatric or central nervous system disease, or of cancer with systemic spread in remission for less than 5 years. - use of any medications started within 14 days (or 5 half-lives, whichever is longer) prior to study drug administration including, prescription medications, nutritional supplements, and over-the-counter medications except for vitamin supplements, hormonal contraception, and recommended doses of acetaminophen, aspirin or ibuprofen - hospitalization for any reason within 60 days prior to the screening visit - history of or positive human immunodeficiency virus (hiv) screen result, or positive blood test for hepatitis b surface antigen (hbsag) or hepatitis b core antibody (hbcab). subjects with positive hepatitis c virus (hcv) antibody at the screening visit are only eligible if they have previously completed treatment for hcv and have confirmatory negative test for hcv rna. - history of drug or alcohol abuse within 1 year prior to screening, or positive test for drugs of potential abuse at screening and admission, where alcohol abuse is defined as regular consumption exceeding 7 drinks/ week for women, and 14 drinks/ week for men. - participation (defined as receipt of dose of investigational agent) in any clinical research study evaluating another investigational drug or therapy within 30 days or at least 5 half-lives (whichever is longer), of the investigational drug prior to the screening visit - blood donation of approximately 1 pint (500 ml) within 60 days prior to dosing, or donation of more than 1 unit of plasma within 30 days prior to the start of study drug dosing - receipt of any transfused blood products within 60 days of the screening visit. - any history of receiving treatment or vaccination against sars-cov-2 - febrile illness within 28 days prior to the first dose of study drug, or other signs or symptoms consistent with sars-cov-2 infection in the judgement of the investigator in the 14 days prior to the first dose of study drug.

- history of any illness or history or presence of clinically significant pathology that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject or collecting samples for analysis. this includes, but is not limited to, a history of relevant drug or food allergies; history of clinically significant cardiovascular, pulmonary, autoimmune, psychiatric or central nervous system disease, or of cancer with systemic spread in remission for less than 5 years. - use of any medications started within 14 days (or 5 half-lives, whichever is longer) prior to study drug administration including, prescription medications, nutritional supplements, and over-the-counter medications except for vitamin supplements, hormonal contraception, and recommended doses of acetaminophen, aspirin or ibuprofen - hospitalization for any reason within 60 days prior to the screening visit - history of or positive human immunodeficiency virus (hiv) screen result, or positive blood test for hepatitis b surface antigen (hbsag) or hepatitis b core antibody (hbcab). subjects with positive hepatitis c virus (hcv) antibody at the screening visit are only eligible if they have previously completed treatment for hcv and have confirmatory negative test for hcv rna. - history of drug or alcohol abuse within 1 year prior to screening, or positive test for drugs of potential abuse at screening and admission, where alcohol abuse is defined as regular consumption exceeding 7 drinks/ week for women, and 14 drinks/ week for men. - participation (defined as receipt of dose of investigational agent) in any clinical research study evaluating another investigational drug or therapy within 30 days or at least 5 half-lives (whichever is longer), of the investigational drug prior to the screening visit - blood donation of approximately 1 pint (500 ml) within 60 days prior to dosing, or donation of more than 1 unit of plasma within 30 days prior to the start of study drug dosing - receipt of any transfused blood products within 60 days of the screening visit. - any history of receiving treatment or vaccination against sars-cov-2 - febrile illness within 28 days prior to the first dose of study drug, or other signs or symptoms consistent with sars-cov-2 infection in the judgement of the investigator in the 14 days prior to the first dose of study drug.